Clinical investigation of medicinal products for the treatment of idiopathic pulmonary fibrosis (IPF) - Scientific guideline

There is currently no scientific guidance from EMA on the clinical investigation of medicinal products for the treatment of idiopathic pulmonary fibrosis (IPF). A guidance document would facilitate development and support marketing authorisation applications for this condition.

Keywords: idiopathic pulmonary fibrosis, clinical development, forced vital capacity

Document

Concept paper on new guidance on the clinical investigation of medicinal products for the treatment of idiopathic pulmonary fibrosis (IPF)

Draft: consultation closed Consultation dates: 30/09/2025 to 31/12/2025 Reference Number: EMA/CHMP/290364/2025 Summary:

Deadline for comments has been extended to 31 January 2026. Comments should be provided using this EUSurvey form. For any technical issues, please contact the EUSurvey Support.